Oral Targeted Therapies and Central Nervous System (CNS) Metastases
The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis i...
Gespeichert in:
| Veröffentlicht in: | CNS drugs 2015-11, Vol.29 (11), p.935-952 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 952 |
|---|---|
| container_issue | 11 |
| container_start_page | 935 |
| container_title | CNS drugs |
| container_volume | 29 |
| creator | Gabay, Michael P. Wirth, Scott M. Stachnik, Joan M. Overley, Colleen L. Long, Katie E. Bressler, Linda R. Villano, John L. |
| description | The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare. |
| doi_str_mv | 10.1007/s40263-015-0283-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751216356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1751216356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-a2036f918e405d9b17e3fa2e2559dc985ea4ddd0875852bb6675ebfc6779e3383</originalsourceid><addsrcrecordid>eNqFkV1LwzAUhoMobk5_gDdS8GZeVPPRJM2lFL9gbheb1yFtT-dG282kFfbvTe0UEUQIJOE85z0fL0LnBF8TjOWNizAVLMSEh5jGLBQHaEiIVCFRLDr8fNNQ4kgO0Ilza4xxxIQ4RgMquGBEiSFKZtaUwcLYJTSQB4tXsGa7AheYOg8SqJsuPAX7vmldMN-5BqpgnEznV8EzNMb5A-4UHRWmdHC2v0fo5f5ukTyGk9nDU3I7CbMI8yY0FDNRKBKD_-YqJRJYYShQzlWeqZiDifI8x7HkMadpKoTkkBaZkFIBYzEboXGvu7WbtxZco6uVy6AsTQ2-PU0kJ5QI5mf7H2WcUcWV8ujlL3S9aW3tB-koL8kkYZ4iPZXZjXMWCr21q8rYnSZYd2bo3gztzdCdGbpr4mKv3KYV5N8ZX9v3AO0B50P1EuyP0n-qfgDLvJFa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1737513713</pqid></control><display><type>article</type><title>Oral Targeted Therapies and Central Nervous System (CNS) Metastases</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gabay, Michael P. ; Wirth, Scott M. ; Stachnik, Joan M. ; Overley, Colleen L. ; Long, Katie E. ; Bressler, Linda R. ; Villano, John L.</creator><creatorcontrib>Gabay, Michael P. ; Wirth, Scott M. ; Stachnik, Joan M. ; Overley, Colleen L. ; Long, Katie E. ; Bressler, Linda R. ; Villano, John L.</creatorcontrib><description>The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.</description><identifier>ISSN: 1172-7047</identifier><identifier>EISSN: 1179-1934</identifier><identifier>DOI: 10.1007/s40263-015-0283-6</identifier><identifier>PMID: 26563196</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Administration, Oral ; Antineoplastic Agents - administration & dosage ; Brain Neoplasms - drug therapy ; Brain Neoplasms - secondary ; Chemotherapy ; Clinical trials ; Confidence intervals ; Drug dosages ; Humans ; Medicine ; Medicine & Public Health ; Melanoma ; Metastasis ; Mutation ; Nervous system ; Neurology ; Neurosciences ; Ovarian cancer ; Patients ; Pharmacotherapy ; Psychiatry ; Psychopharmacology ; Response rates ; Review Article ; Studies ; Toxicity</subject><ispartof>CNS drugs, 2015-11, Vol.29 (11), p.935-952</ispartof><rights>Springer International Publishing Switzerland 2015</rights><rights>Copyright Springer Science & Business Media Nov 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-a2036f918e405d9b17e3fa2e2559dc985ea4ddd0875852bb6675ebfc6779e3383</citedby><cites>FETCH-LOGICAL-c405t-a2036f918e405d9b17e3fa2e2559dc985ea4ddd0875852bb6675ebfc6779e3383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40263-015-0283-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40263-015-0283-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26563196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gabay, Michael P.</creatorcontrib><creatorcontrib>Wirth, Scott M.</creatorcontrib><creatorcontrib>Stachnik, Joan M.</creatorcontrib><creatorcontrib>Overley, Colleen L.</creatorcontrib><creatorcontrib>Long, Katie E.</creatorcontrib><creatorcontrib>Bressler, Linda R.</creatorcontrib><creatorcontrib>Villano, John L.</creatorcontrib><title>Oral Targeted Therapies and Central Nervous System (CNS) Metastases</title><title>CNS drugs</title><addtitle>CNS Drugs</addtitle><addtitle>CNS Drugs</addtitle><description>The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.</description><subject>Administration, Oral</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Response rates</subject><subject>Review Article</subject><subject>Studies</subject><subject>Toxicity</subject><issn>1172-7047</issn><issn>1179-1934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkV1LwzAUhoMobk5_gDdS8GZeVPPRJM2lFL9gbheb1yFtT-dG282kFfbvTe0UEUQIJOE85z0fL0LnBF8TjOWNizAVLMSEh5jGLBQHaEiIVCFRLDr8fNNQ4kgO0Ilza4xxxIQ4RgMquGBEiSFKZtaUwcLYJTSQB4tXsGa7AheYOg8SqJsuPAX7vmldMN-5BqpgnEznV8EzNMb5A-4UHRWmdHC2v0fo5f5ukTyGk9nDU3I7CbMI8yY0FDNRKBKD_-YqJRJYYShQzlWeqZiDifI8x7HkMadpKoTkkBaZkFIBYzEboXGvu7WbtxZco6uVy6AsTQ2-PU0kJ5QI5mf7H2WcUcWV8ujlL3S9aW3tB-koL8kkYZ4iPZXZjXMWCr21q8rYnSZYd2bo3gztzdCdGbpr4mKv3KYV5N8ZX9v3AO0B50P1EuyP0n-qfgDLvJFa</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Gabay, Michael P.</creator><creator>Wirth, Scott M.</creator><creator>Stachnik, Joan M.</creator><creator>Overley, Colleen L.</creator><creator>Long, Katie E.</creator><creator>Bressler, Linda R.</creator><creator>Villano, John L.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20151101</creationdate><title>Oral Targeted Therapies and Central Nervous System (CNS) Metastases</title><author>Gabay, Michael P. ; Wirth, Scott M. ; Stachnik, Joan M. ; Overley, Colleen L. ; Long, Katie E. ; Bressler, Linda R. ; Villano, John L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-a2036f918e405d9b17e3fa2e2559dc985ea4ddd0875852bb6675ebfc6779e3383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Oral</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Response rates</topic><topic>Review Article</topic><topic>Studies</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gabay, Michael P.</creatorcontrib><creatorcontrib>Wirth, Scott M.</creatorcontrib><creatorcontrib>Stachnik, Joan M.</creatorcontrib><creatorcontrib>Overley, Colleen L.</creatorcontrib><creatorcontrib>Long, Katie E.</creatorcontrib><creatorcontrib>Bressler, Linda R.</creatorcontrib><creatorcontrib>Villano, John L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>CNS drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gabay, Michael P.</au><au>Wirth, Scott M.</au><au>Stachnik, Joan M.</au><au>Overley, Colleen L.</au><au>Long, Katie E.</au><au>Bressler, Linda R.</au><au>Villano, John L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Targeted Therapies and Central Nervous System (CNS) Metastases</atitle><jtitle>CNS drugs</jtitle><stitle>CNS Drugs</stitle><addtitle>CNS Drugs</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>29</volume><issue>11</issue><spage>935</spage><epage>952</epage><pages>935-952</pages><issn>1172-7047</issn><eissn>1179-1934</eissn><abstract>The purpose of our review is to summarize the clinical activity of oral targeted agents against brain metastases. This includes BRAF inhibitors (dabrafenib and vemurafenib), human epidermal growth factor receptor inhibitors (lapatinib, gefitinib, erlotinib, and afatinib), multi-kinase angiogenesis inhibitors (sorafenib, sunitinib, pazopanib, and vandetanib), and ALK/c-MET (crizotinib) and ALK/IGF-1 (ceritinib) inhibitors. Effective systemic therapies are needed for long-term benefit in brain metastases and documentation of intracranial activity for many therapies is poor. Our review provides a summary of the literature with pertinent data for clinicians. This is needed as subjects with brain metastases are often prevented from enrolling in clinical trials and investigations focused on systemic therapies for brain metastases are rare.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26563196</pmid><doi>10.1007/s40263-015-0283-6</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1172-7047 |
| ispartof | CNS drugs, 2015-11, Vol.29 (11), p.935-952 |
| issn | 1172-7047 1179-1934 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751216356 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Antineoplastic Agents - administration & dosage Brain Neoplasms - drug therapy Brain Neoplasms - secondary Chemotherapy Clinical trials Confidence intervals Drug dosages Humans Medicine Medicine & Public Health Melanoma Metastasis Mutation Nervous system Neurology Neurosciences Ovarian cancer Patients Pharmacotherapy Psychiatry Psychopharmacology Response rates Review Article Studies Toxicity |
| title | Oral Targeted Therapies and Central Nervous System (CNS) Metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A16%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Targeted%20Therapies%20and%20Central%20Nervous%20System%20(CNS)%20Metastases&rft.jtitle=CNS%20drugs&rft.au=Gabay,%20Michael%20P.&rft.date=2015-11-01&rft.volume=29&rft.issue=11&rft.spage=935&rft.epage=952&rft.pages=935-952&rft.issn=1172-7047&rft.eissn=1179-1934&rft_id=info:doi/10.1007/s40263-015-0283-6&rft_dat=%3Cproquest_cross%3E1751216356%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1737513713&rft_id=info:pmid/26563196&rfr_iscdi=true |